Q2

QUARTERLY REPORT

APRIL – JUNE 2026

SENZIME

SECOND QUARTER OF 2026:

STRONG SENSOR SALES AND IMPROVED MARGINS, DESPITE CONTINUED U.S. MONITOR MARKET HEADWINDS

Sensor sales continued their strong momentum, driven by expanding utilization of TetraGraph systems in the market. While U.S. hospital hardware market conditions remained challenging during the second quarter, we have increased our focus on operational fundamentals resulting in improved margins, a further reduction in our cost base, and a significantly strengthened cash flow.

Our objective of reaching profitability within Q4 remains firmly on track.

- **48% growth in sensor sales, in constant currencies**
- **15% reduction in operating expenses**
- **27% improvement in EBITDA**
- **46% improvement in cash flow**

NET SALES SECOND QUARTER (MSEK)



QUARTERLY REPORT APRIL–JUNE 2026

SECOND QUARTER 2026 (1 APRIL – 30 JUNE)

- Net sales amounted to TSEK 24,671 (25,695), a decrease of 4 %
- Currency-adjusted net sales decreased by 1 %
- Sales in the US amounted to TSEK 18,716 (19,930), a decrease of 6%
- Sales in the International markets amounted to TSEK 5,955 (5,765), an increase of 3%
- Gross margin before depreciation amounted to 65.7 % (61.8)
- Operating costs amounted to TSEK 34,201 (40,207)
- Operating profit before depreciation amounted to TSEK -17,267 (-23,573)
- Results after financial items amounted to TSEK -21,385 (-34,159)
- Earnings per share amounted to SEK -0.14 (-0.24)
- Cash and cash equivalents as of June 30th amounted to TSEK 37,112 (132,162)

SIGNIFICANT EVENTS DURING SECOND QUARTER

- Strengthened U.S. leadership with the recruitment of a new Vice President of US Sales and the appointment of a Vice President of Clinical and Medical Affairs.
- Secured procurement agreements with all three leading American Group Purchasing Organizations (GPOs) for the TetraGraph system
- Expanded U.S. business with a new contract at a top-ranked children's hospital in the eastern U.S., expanded contract with southeast based hospital system and strategic hospital orders within leading US integrated healthcare delivery network
- Received additional FDA Class II 510(k) clearance for the TetraGraph system, expanding its regulatory footprint.
- Launched two new products: TetraSens® EMG sensor, developed and manufactured with sustainability at its core, and TetraAnalytics™, a cloud-based analysis tool that enhances the clinical value of the TetraGraph® system.
- Gained regulatory approval in Brazil, with clearance from ANVISA opening the door to sales in the Brazilian market.
- Senzime secures additional business in the US; signs contract with top-ranked children's hospital based in the eastern US after a competitive evaluation

EVENTS AFTER THE END OF THE SECOND QUARTER

- Senzime signs long-term partnership agreement with Philips Medical Systems

FIRST HALF YEAR 2026 (1 JANUARY – 30 JUNE)

- Net sales amounted to TSEK 47,904 (49,195), a decrease of 3 %
- Currency-adjusted net sales increased by 4 %
- Sales in the US amounted to TSEK 33,591 (35,481), a decrease of 6%
- Sales in the International markets amounted to TSEK 14,383 (13,714), an increase of 5%
- Gross margin before depreciation amounted to 64.4 % (63.8)
- Operating costs amounted to TSEK 69,763 (77,504)
- Operating profit before depreciation amounted to TSEK -37,469 (-44,411)
- Results after financial items amounted to TSEK -44,627 (-69,981)
- Earnings per share amounted to SEK -0.28 (-0.50)

SIGNIFICANT EVENTS DURING FIRST HALF YEAR OF 2026

- Senzime secures new contracts with hospitals in the US market including installation of 60 Next-generation TetraGraph systems at an Ivy League hospital, new contracts for delivery to hospitals within one of the world's largest integrated healthcare systems which, if fully system-wide, could be the largest deal to date for Senzime in the US. Senzime wins expanded contract within leading hospital system in the Southeastern US for an additional 65 TetraGraph systems. Senzime secures additional contract with top-ranked children's hospital in the Eastern US region following a competitive evaluation.
- Senzime launches new products, TetraSens® EMG sensor specifically developed and manufactured with sustainability in mind. Launch of TetraAnalytics™, a new cloud-based analysis tool that complements and enhances the benefits of the TetraGraph® system. Senzime launches TetraCom Connectivity Platform that enables universal integration of the TetraGraph system directly into leading electronic medical record systems.
- Strengthening of the US operations through the appointment of a new Vice President of US Sales and appointment of Vice President of Clinical and Medical Affairs.
- TetraGraph system received another FDA Class II 510(k) clearance as well as approval from the Brazilian health authority ANVISA.
- Senzime signs a credit facility totaling SEK 50 million. The facility has been issued on market terms by Crafoord, Segulah and a number of major existing shareholders as well as DBT Capital, part of Noba Bank Group.

KPI's SECOND QUARTER 2026

TSEK	Q2 2026	Q2 2025	HALF YEAR 2026	HALF YEAR 2025	TOT YEAR 2025
Net Sales	24,671	25,695	47,904	49,195	104,022
EBITDA	-17,267	-23,573	-37,469	-44,411	-99,051
Profit (loss) after financial items	-21,385	-34,159	-44,627	-69,681	-139,039
Earnings per share (SEK)	-0.14	-0.24	-0.28	-0.50	-0.93
Gross margin excl. amortization (%)	65,7	61.8	64,4	63.8	52.6
Solidity (%)	81.1	85.3	81.1	85.3	82.3
Sales Growth (%)	-4.0	72.3	-2,6	82.0	77.9

Net sales Q2 (MSEK)



Net Sales R-12 months TSEK



Net Sales Sensors R 12-months TSEK



Total amount of shipped TetraGraph-systems[1]



Comment: (1) Refers to all accumulated deliveries of TetraGraph monitors to end customers, distributors and partners. Some of the delivered base are still in stock at sales partners or has not yet been installed in a hospital environment

SALES OVERVIEW

TSEK Q2 Apr-Jun	Reported 2026	Reported 2025	Reported Growth	Currency adjusted Growth
US	**18,716**	**19,930**	**-6%**	**-3%**
Devices/other	3,520	10,019	-65%	-64%
Disposables	15,196	9,911	53%	58%
Europe	**3,322**	**3,612**	**-8%**	**-7%**
Devices/other	653	1,458	-55%	-55%
Disposables	2,669	2,154	24%	25%
RoW	**2,633**	**2,153**	**22%**	**24%**
Devices/other	635	419	52%	60%
Disposables	1,998	1,735	15%	16%
Total Q2	**24,671**	**25,695**	**-4%**	**-1%**
Devices/other	4,808	11,896	-60%	-58%
Disposables	19,863	13,800	44%	48%

TSEK H1 Jan-Jun	Reported 2026	Reported 2025	Reported Growth	Currency adjusted Growth
US	**33,521**	**35,481**	**-6%**	**3%**
Devices/other	6,056	16,307	-63%	-60%
Disposables	27,465	19,174	43%	57%
Europe	**8,178**	**7,428**	**10%**	**13%**
Devices/other	2,643	3,374	-22%	-20%
Disposables	5,535	4,054	37%	41%
RoW	**6,204**	**6,286**	**-1%**	**2%**
Devices/other	1,572	1,452	8%	25%
Disposables	4,632	4,834	-4%	-2%
Total H1	**47,904**	**49,195**	**-3%**	**4%**
Devices/other	10,271	21,133	-51%	-48%
Disposables	37,633	28,062	34%	44%

Net Sales by product group (Q2)



Net Sales by region (Q2)



Accumulated volume of delivered TetraSens sensors



This is Senzime.

Senzime is a global medical technology company that develops algorithm-based patient monitoring systems with the goal of eliminating anesthesia related complications in over 100 million patients every year.

Our systems enable precision-based monitoring of patients during and after surgery. It is about ensuring the correct individual dose of anesthesia-related drugs, indicating when it is safe to breathe again and enabling early identification of post-operative complications.

Our foundation is based on extensive research and collaborations with leading academic institutions such as Mayo Clinic, Harvard, and Massachusetts General Hospital. Our systems meet the requirements of new clinical guidelines in the US, Europe, and many other countries.

We have commercial operations covering over 30 markets with subsidiaries in the US and Germany, as well as several licensing and distribution partnerships in other regions. And we are listed on Nasdaq Main Market Stockholm with institutional owners and a world-class team.

SENZIME

CEO COMMENT

STRONG SENSOR SALES AND IMPROVED MARGINS, DESPITE CONTINUED U.S. MONITOR MARKET HEADWINDS

Sensor sales continued their strong momentum, driven by expanding utilization of TetraGraph systems in the market. While U.S. hospital hardware market conditions remained challenging during the second quarter, we have increased our focus on operational fundamentals resulting in improved margins, a further reduction in our cost base, and a significantly strengthened cash flow. Our objective of reaching profitability within Q4 remains firmly on track.

As in the first quarter, second-quarter sales were affected by a slower U.S. market, with several expected hospital contracts continuing to see delays. Despite this, we secured several important new agreements during the quarter, underscoring the underlying strength of our commercial pipeline. These included first deliveries to one of the world's largest integrated delivery networks (IDNs), with potential to encompass more than 150 hospitals; an expanded agreement with a leading IDN in the southeastern U.S and a new contract with another top-ranked U.S. children's hospital.

The underlying business continues to develop strongly. Sensor sales increased by 48 percent in local currencies. Recurring sensor sales now account for approximately 80 percent of our revenue, reflecting the continued increase in utilization of TetraGraph systems across our approximately 750 hospital customers worldwide.

We have now secured TetraGraph's inclusion in purchasing agreements with all three leading U.S. Group Purchasing Organizations (GPOs), a significant commercial milestone as more than 5,000 U.S. hospitals are affiliated with a GPO. While GPO listings do not generate immediate revenue, they remove key structural barriers in the procurement process and strengthen our ability to convert our sales pipeline into commercial contracts.

Our U.S. organization was further strengthened during the quarter through key leadership appointments. Josi Wood joined as new Vice President of U.S. Sales, and Jen Sanders was appointed as Vice President of Clinical and Medical Affairs. These are two highly experienced leaders with the capability to take our U.S. business to the next level. Both are important members of Senzime's global leadership team.

Shortly before the quarterly report, we announced the largest and most important commercial agreement in Senzime's history. We signed a long-term strategic partnership with Philips Medical Systems, the global leader in patient monitoring. The partnership is the result of more than ten years of technology development and commercial investment and represents strong validation of our technology, intellectual property, and long-term strategy.

Under the agreement, we will jointly develop new products that will be commercialized through Philips' global sales organization. The partnership significantly expands our commercial reach and multiplies our addressable market by tens of thousands of hospitals worldwide. It complements our existing product portfolio and sales channels, and we expect it to accelerate the global adoption of our core technologies. I believe this collaboration will generate substantial revenue over time and create significant long-term shareholder value.

Our pace of innovation remains high. During the quarter, we launched the new TetraSens, an EMG sensor now manufactured in Europe using a new sustainable production process. We also launched TetraAnalytics™, a cloud-based analytics platform that generates clinical and operational insights to help hospitals comply with clinical guidelines and increase the utilization of neuromuscular monitoring.

The TetraGraph system also received an additional FDA 510(k) clearance. The clearance, based on a submission filed in April 2026, expands the system's capabilities and further strengthens its competitive position in the U.S. market.

We have continued to strengthen our presence in Latin America through new business in markets including Mexico and Chile. Toward the end of the quarter, we also received regulatory approval from the Brazilian health authority, ANVISA, enabling commercialization in the world's eleventh-largest economy. Brazil is the largest healthcare market in Latin America, and clinical guidelines recommend neuromuscular monitoring whenever neuromuscular blocking agents are used, creating attractive conditions for our continued expansion in the region.

Our gross margin continued to improve, reaching 65.7 percent in the second quarter, compared with 61.8 percent in the second quarter of 2025. We continue to improve our unit economics while U.S. tariffs continue to impact our gross margin. We received our first U.S. tariff repayment in early July of USD 116 thousand and expecting additional USD 350 thousand to be repaid over coming quarters.

We reduced our operating expenses by 15 percent compared with the second quarter of 2025. As a result, EBITDA improved by approximately 27 percent compared with the corresponding quarter last year.

Cash flow in the second quarter improved to SEK -13.7 million, compared with SEK -25.3 million in the same quarter last year, representing an improvement of approximately 45 percent. This reflects stronger gross margins, lower operating expenses, and optimized working capital management.

We have now shipped nearly 6,000 TetraGraph systems, with more than half delivered during the past two years. With a potential of more than 160,000 operating rooms across our current target markets alone, market penetration remains at an early stage. The Philips partnership further expands our addressable market by providing access to entirely new market segments in more than 70 countries.

We remain firmly committed to achieving profitability by the end of 2026. Despite a slower start to the year in terms of new hospital contracts, we have a strong sales pipeline, a growing installed base, and an increasing share of recurring revenue. Combined with continued margin improvements and disciplined cost management, this provides a solid foundation for returning to strong growth.

With our new strategic partnership with Philips, a strengthened position in the U.S. market, and a continued high pace of innovation, we are well positioned for the next phase of Senzime's development. I look forward to the remainder of the year with great confidence.

Uppsala, July 18, 2025
Philip Siberg, CEO

Comments to the report

Revenue and profit in the second quarter 2026

The Group's net sales for the second quarter of 2026 amounted to TSEK 24,671 (25,695), a decrease of 4 percent compared to the corresponding quarter of the previous year. Adjusted to currency changes, sales decreased by 1 percent. Sales were mainly negatively affected by delayed purchasing processes in the US market.

Sales of disposable sensors increased by 48 percent in constant currencies and 44 percent in reported figures. Number of units sold amounted to 132,175, corresponding to an increase of 44 percent. Sales of instruments/other decreased by 58 percent in constant currencies and 60 percent in reported figures, corresponding to a decrease of TSEK 7,088. During the quarter, 239 TetraGraph systems were delivered compared to 727 systems in the second quarter of 2025.

The gross margin before depreciation in the second quarter amounted to 65.7 percent, compared to 61.8 percent for the corresponding quarter of the previous year. An increase mainly attributable to positive effects of lower production costs for Next-gen TetraGraph, price increase to certain customers and positive effects from customer and product mix. We are conducting extensive innovation work aimed at continuously launching products that strengthen the gross margin to levels above 70 percent in the long term.

During the second quarter, the Group's total operating expenses amounted to TSEK 34,201 (40,207). Direct operating expenses amounted to TSEK 34,081 (40,361) and other operating income and operating expenses, attributable to currency-related translation of balance sheet items, amounted to TSEK 120 (-154).

The operating result during the second quarter amounted to TSEK -23,333 compared to TSEK -29,291 in the corresponding quarter last year. An improvement of 6 million SEK or 20% compared to last year. Profit after financial items amounted to TSEK -21,385 compared to TSEK -34,159 in the corresponding period last year. An improvement in profit of 12.8 million SEK or 37% vs. the same period last year.

Revenue and profit January – June 2026

The Group's net sales for the period January - June 2026 amounted to TSEK 47,904 (49,195), corresponding to a decrease of 3 percent compared to the corresponding period last year. Adjusted for currency changes, sales increased by 4 percent. We note a larger negative effect of currency impact mostly related to the weaker dollar against the Swedish krona compared to the same period last year.

Sales of disposable sensors increased by 44 percent in constant currencies and 34 percent in reported figures. Number of units sold amounted to 254,125, corresponding to an increase of 39 percent. Sales of instruments/other decreased by 48 percent in constant currencies and 51 percent in reported figures, corresponding to a decrease of TSEK 10,862. During the period, 615 TetraGraph systems were delivered compared to 1,170 systems during the same period in 2025.

The gross margin before depreciation for the first half of 2026 amounted to 64.4 percent, compared to 63.8 percent for the corresponding period in the previous year. The underlying gross margin, adjusted for currency and customs effects, amounted to 67.4 percent compared to 63.8% for the same period in 2025. The improvement is driven by lower production costs for the new Next-gen TetraGraph as well as the first deliveries of the new TetraSens, which also have lower production costs. We also note some positive effects from the customer and product mix. Our ongoing innovation work is focused on gradually launching products that over time strengthen the gross margin to levels above 70 percent.

During the first half of 2026, the Group's total operating expenses amounted to TSEK 69,763 (77,504). Direct operating expenses amounted to TSEK 70,034 (76,790) and other operating income and operating expenses, attributable to currency-related translation of balance sheet items, amounted to TSEK -271 (714). We continue with investments and smart resource allocations. With good cost control, reduced one-off costs and positive effects of a weaker dollar on operating expenses attributable to our operations in the USA, we have reduced total operating expenses by TSEK 7,742 compared to the same period last year.

Operating profit for the first half of 2026 amounted to TSEK -49,219 compared to TSEK -56,187 in the same period last year. An improvement of 7 million SEK, corresponding to 12%. Profit after financial items amounted to TSEK -44,627 compared to TSEK -69,681 in the same period last year. An improvement in profit by 25.1 million SEK or 36% vs. the same period last year.

Cash-flow and Investments

Cash flow from operating activities including changes in working capital amounted to TSEK-13,684 (-25,348) for the second quarter. The negative cash flow is mainly due to the negative result. Cash flow from investing activities for the second quarter amounted to TSEK -4,202 (-4,960). Investments during the period are largely related to capitalization of development projects.

Cash flow from financing activities amounted to TSEK -450 (100,561) during the second quarter. Negative cash flow is mainly related to payments related to leasing costs.

Cash flow from operating activities including changes in working capital for the period January - June 2026 amounted to TSEK -36,712 (-57,647). The negative cash flow is mainly explained by the negative result for the period, partly offset by a positive change in working capital, mainly as a result of inventory optimization and improved payments of accounts receivable.

Cash flow from investing activities for the period Jan - June 2026 amounted to TSEK -7,000 (-9,994) mainly related to the capitalization of development projects.

Cash flow from financing activities for the period January - June 2026 amounted to TSEK 6,616 (99,328). During the period January-June, TSEK 7,500 of the total credit facility of TSEK 42,500 was utilized due to contractual terms, not the company's liquidity needs. The negative item of TSEK -884 mainly relates to lease-related payments.

Financial position

At the end of the period, the company's cash and cash equivalents amounted to TSEK 37,112 (132,162), the group's equity to TSEK 263,840 (371,400) and the equity ratio was 81.1 percent (85.3). The company's monthly burn rate has decreased from an average of 11 million SEK per month in 2025 to an average of 6 million SEK in the last quarter of 2026. To further secure possible peaks in working capital needs, the company secured a credit facility for a total of 42.5 million SEK on market terms. During the period January - June, 7.5 million SEK of the credit was used due to contractual terms and not due to the company's liquidity needs.

The board of directors is continuously working to secure the company's long-term financing to ensure the operation of the business, including investments and ventures. The company's growth plan is continuously balanced against the financial funds available at any given time.

Stock options

At the time of publication of this interim report, there are five employee stock option programs with a total of 5,950,000 granted options and 700,000 hedge options. A total of 489,000 employee stock options has expired to date and the remaining 5,461,000 employee stock options, if fully exercised, would result in a dilution of 3.92 percent. The corresponding figure excluding hedge options is 3.47 percent. For more information, see Note 10.

Parent company and subsidiaries

The majority of the group's operations are conducted in the parent company. For comments on the parent company's results, refer to the comments submitted for the group. The American company Respiratory Motion Inc. was acquired in the third quarter of 2022 and is a 100 percent wholly owned subsidiary of Senzime AB (publ.). The US subsidiary Senzime Inc. started its operational activities in the second quarter of 2020. Sales in the US are carried out under its own auspices. In the first quarter of 2021, the German subsidiary Senzime GmbH started its operations. The group's two other subsidiaries only hold certain rights which have been licensed to the parent company against payment in the form of royalties.

Sustainability

Senzime's operations contribute to improved global health and patient safety by reducing anesthesia and breathing-related complications and lowering healthcare costs in connection with surgical procedures and emergency treatments. Senzime's sustainability work supports commitment to patients and strives for sustainable development based on responsible action and in line with the fundamental values.
In 2023, Senzime signed an agreement with the UN Global Compact, which means that the company commits to operating according to their 10 principles, which include labor law, human rights, anti-corruption and the environment. In 2025, the company's ISO 14001 environmental management system was recertified for fiscal year 2026.

Significant events in the quarter

Strengthened U.S. leadership with the recruitment of a new Vice President of US Sales and the appointment of a Vice President of Clinical and Medical Affairs.

Secured procurement agreements with all three leading American Group Purchasing Organizations (GPOs) for the TetraGraph system

Expanded U.S. business with a new contract at a top-ranked children's hospital in the eastern U.S., expanded contract with southeast based hospital system and strategic hospital orders within leading US integrated healthcare delivery network

Received additional FDA Class II 510(k) clearance for the TetraGraph system, expanding its regulatory footprint.

Launched two new products: TetraSens® EMG sensor, developed and manufactured with sustainability at its core, and TetraAnalytics™, a cloud-based analysis tool that enhances the clinical value of the TetraGraph® system.

Gained regulatory approval in Brazil, with clearance from ANVISA opening the door to sales in the Brazilian market.

Senzime secures additional business in the US; signs contract with top-ranked children's hospital based in the eastern US after a competitive evaluation

Significant events after the end of the quarter

Senzime and Philips Medical Systems signs long-term development and commercialization partnership.

Receipt of first U.S. tariff repayment of USD 116 thousand, with expected additional USD 350 thousand to be repaid over coming quarters.

Risks and uncertainty factors

Several risk factors can have a negative impact on the operations of Senzime. It is therefore of great importance to consider relevant risks in addition to the company's growth opportunities. A description of the Group's significant financial and business risks, including new US tariffs, can be found in the administration report and in the annual report for 2025.

The geopolitical situation

Senzime has no operations in Russia, Ukraine, Israel, Iran, Lebanon or Palestine. The company's gross margin has been impacted by new US tariffs introduced during the spring of 2025. Furthermore, the company notes that the US hospital market was affected by concerns regarding inflation and rising costs, which temporarily led to certain purchasing decisions for new capital equipment being postponed.

Review

This interim report has not been subject to review by the company's auditors.

Board of Directors' certification

The Board of Directors and CEO certify that this interim report gives a true and fair view of the parent company's and the group's operations, financial position, and results of operations, and reviews the significant risks and uncertainties faced by the parent company and companies in the group.

Uppsala July 16, 2026

Per Wold-Olsen
Chairman of the Board

Adam Dahlberg
Vice Chairman of the Board

Sorin Brull
Board member

Wolfgang Reim
Board member

Ann Costello
Board member

Lars Axelson
Board member

Philip Siberg
Chief Executive Officer

Condensed Consolidated Statement of Comprehensive Income

		Q2		Jan-Jun		Full-year
Amounts in SEK thousands	Note	2026	2025	2026	2025	2025
Net sales	2	24,671	25,695	47,904	49,195	104,022
Cost of goods sold	3	-13,803	-14,778	-27,360	-27,877	-69,330
Gross profit (loss)		**10,868**	**10,917**	**20,544**	**21,317**	**34,692**
Development expenditure	4	-5,822	-5,810	-11,489	-10,210	-22,852
Selling expenses	4	-20,436	-24,070	-41,525	-48,047	-98,086
Administrative expenses	4 & 5	-7,823	-10,481	-17,020	-18,533	-34,733
Other operating income		2,776	6,796	7,772	9,678	16,543
Other operating expenses		-2,896	-6,642	-7,501	-10,392	-18,139
Earnings before interest and taxes		**-23,333**	**-29,291**	**-49,219**	**-56,187**	**-122,575**
Financial income		2,347	156	5,628	375	790
Financial expenses		-399	-5,024	-1,036	-13,868	-17,253
Financial items - net		**1,948**	**-4,869**	**4,592**	**-13,494**	**-16,463**
Profit (loss) after financial items		**-21,385**	**-34,159**	**-44,627**	**-69,681**	**-139,039**
Income tax		24	-190	754	670	1,619
Profit (-loss) for the period		**-21,361**	**-34,349**	**-43,873**	**-69,011**	**-137,419**

Condensed Consolidated Statement of Comprehensive Income

		Q2		Jan-Jun		Full-year
Amounts in SEK thousands	**Note**	**2026**	**2025**	**2026**	**2025**	**2025**
Profit (-loss) for the period		**-21,361**	**-34,349**	**-43,873**	**-69,011**	**-137,419**
Other comprehensive income						
Items reclassifiable to profit or loss						
Conversion differences		1,251	-1,898	2,704	-7,400	-9,477
Total comprehensive income		**-20,110**	**-36,247**	**-41,169**	**-76,410**	**-146,896**

The year's profit (loss) and total comprehensive income is attributable in its entirety to the parent company's shareholders.

Earnings per share, calculated on the period's earnings attributable to the parent company's shareholders.

		Q2		Jan-Jun		Full-year
SEK	**Note**	**2026**	**2025**	**2026**	**2025**	**2025**
Weighted average number of shares, before dilution	6	157,215,046	140,722,824	157,215,046	136,955,877	147,067,962
Weighted average number of shares, after dilution	6	157,215,046	140,722,824	157,215,046	136,955,877	147,067,962
Earnings per share, basic and diluted, SEK	6	**-0.14**	**-0.24**	**-0.28**	**-0.50**	**-0.93**

Condensed Consolidated Balance Sheet

Assets

Amounts in SEK thousands	June 30 2026	June 30 2025	December 31 2025
ASSETS			
Non-current assets			
Intangible assets	222,806	227,106	219,000
Property plant and equipment	4,727	4,205	4,462
Rights of use	13,609	14,982	13,850
Other financial assets	4,328	4,844	4,614
Total non-current assets	**245,470**	**251,137**	**241,927**
Current assets			
Inventories	21,478	30,964	25,168
Trade receivables and other receivables	13,788	13,250	17,595
Other receivables	1,258	3,461	3,835
Prepaid expenses and accrued income	6,295	4,245	7,311
Cash and cash equivalents	37,112	132,162	73,975
Total current assets	**79,931**	**184,082**	**127,884**
TOTAL ASSETS	**325,401**	**435,219**	**369,811**

Condensed Consolidated Balance Sheet

Equity and Liabilities

Amounts in SEK thousands	June 30 2026	June 30 2025	December 31 2025
EQUITY AND LIABILITIES			
Equity	**263,840**	**371,400**	**304,461**
LIABILITIES			
Non-current liabilities			
Provisions	4,378	4,547	4,614
Interest-bearing liabilities	7,500	-	-
Lease liability	11,903	13,250	12,384
Deferred tax liability	13,625	16,406	14,546
Total non-current liabilities	**37,406**	**34,203**	**31,545**
Current liabilities			
Lease liability	1,967	1,691	1,630
Trade payables	4,598	7,418	9,595
Other current liabilities	4,740	8,379	7,332
Accrued expenses	12,850	12,128	15,248
Total current liabilities	**24,155**	**29,616**	**33,805**
TOTAL EQUITY AND LIABILITIES	**325,401**	**435,219**	**369,811**

Condensed Consolidated Statement of Change in Equity

	Attributable to parent company´s shareholders				
Amounts in SEK thousands	**Share capital**	**Other contributed capital**	**Reserves**	**Retained earnings incl.profit (loss) for the year**	**Total equity**
Adjusted opening balance as of 1 January 2025	**16,647**	**959,021**	**9,102**	**-638,913**	**345,857**
Profit (-loss) for the period				-69,011	-69,011
Other comprehensive income			-7,400		-7,400
Total comprehensive income	**-**	**-**	**-7,400**	**-69,011**	**-76,411**
Transactions with shareholders in their capacity as owners					
Employee stock options				535	535
New share issue	2,917	104,263			107,180
Expenses attributable to new share issues		-5,761			-5,761
Total transactions with shareholders	**2,917**	**98,502**	**-**	**535**	**101,954**
Closing equity June 30 2025	**19,564**	**1,057,523**	**1,702**	**-707,389**	**371,400**

	Attributable to parent company´s shareholders				
Amounts in SEK thousands	**Share capital**	**Other contributed capital**	**Reserves**	**Retained earnings incl.profit (loss) for the year**	**Total equity**
Opening balance as of January 1, 2026	**19,652**	**1,060,259**	**-374**	**-775,076**	**304,461**
Profit (-loss) for the period				-43,873	-43,873
Other comprehensive income			2,704		2,704
Total comprehensive income	**-**	**-**	**2,704**	**-43,873**	**-41,169**
Transactions with shareholders in their capacity as owners					
Employee stock options				548	548
New share issue					
Expenses attributable to new share issues					
Total transactions with shareholders	**-**	**-**	**-**	**548**	**548**
Closing equity June 30 2026	**19,652**	**1,060,259**	**2,330**	**-818,401**	**263,840**

Condensed Consolidated Statement of Cash Flow

	Q2		Jan-Jun		Full-year
Amounts in SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Cash flow from operating activities					
Earnings before interest and taxes	-23,333	-29,290	-49,219	-56,187	-122,575
Adjustment for non-cash items					
Depreciation and amortization	6,066	5,718	11,750	11,776	23,524
Other non-cash items	197	-2,674	-130	128	2,152
Interest paid	-399	-8	-1,036	-11	-20
Interest received	50	66	83	129	812
Income tax paid	-620	-6	-736	-83	-983
Cash flow from operating activities before change in working capital	**-18,039**	**-26,194**	**-39,288**	**-44,248**	**-97,091**
Cash flow from change in working capital					
Increase/decrease in inventories	2,184	-1,673	4,187	-4,781	667
Increase/decrease in trade receivables	2,996	2,053	4,311	-4,563	-9,200
Increase/decrease in operating receivables	2,778	1,951	3,971	123	-3,385
Increase/decrease in trade payables	-3,324	-696	-4,583	-1,406	-20
Increase/decrease in operating payables	-279	-789	-5,310	-2,772	-69
Total change in working capital	**4,355**	**846**	**2,576**	**-13,399**	**-12,006**
Cash flow from operating activities	**-13,684**	**-25,348**	**-36,712**	**-57,647**	**-109,097**
Cash flow from investing activities					
Investments in tangible assets	12	-731	-665	-1,115	-2,744
Investments in intangible assets	-4,214	-4,229	-6,335	-8,879	-15,352
Cash flow from (-used in) investing activities	**-4,202**	**-4,960**	**-7,000**	**-9,994**	**-18,097**
Cash flow from financing activities					
Proceeds from loans	-	-	7,500	-	-
Payments made for repayment of lease liabilities	-450	-919	-884	-2,091	-3,434
New share issue, net of transaction expenses	-	101,480	-	101,419	104,243
Cash flow from financing activities	**-450**	**100,561**	**6,616**	**99,328**	**100,809**
Decrease/increase in cash and cash equivalents	-18,336	70,253	-37,096	31,687	-26,385
Cash and cash equivalents at beginning of period	55,353	62,059	73,975	100,941	100,941
Exchange difference in cash and cash equivalents	95	-150	233	-466	-582
Cash and cash equivalents at end of period	**37,112**	**132,162**	**37,112**	**132,162**	**73,975**

Parent company Income Statement

Amounts in SEK thousands	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Net sales	7,464	18,934	22,086	46,311	82,827
Cost of goods sold	-6,261	-12,155	-16,361	-22,471	-59,577
Gross profit (loss)	**1,203**	**6,779**	**5,725**	**23,840**	**23,250**
Development expenditure	-4,079	-4,551	-8,557	-7,902	-17,898
Selling expenses	-15,353	-3,479	-18,996	-6,881	-86,604
Administrative expenses	-9,332	-11,918	-19,501	-20,904	-39,946
Other operating income	2,173	2,002	6,705	4,029	9,386
Other operating expenses	-2,488	-2,683	-6,477	-6,410	-12,211
Earnings before interest and taxes	**-27,876**	**-13,850**	**-41,101**	**-14,228**	**-124,023**
Financial income	4,381	2,043	9,603	4,218	8,586
Financial expenses	-197	-4,733	-619	-13,259	-16,247
Financial items - net	**4,184**	**-2,690**	**8,984**	**-9,041**	**-7,660**
Profit (loss) after financial items	**-23,692**	**-16,540**	**-32,117**	**-23,269**	**-131,683**
Profit (-loss) for the period	**-23,692**	**-16,540**	**-32,117**	**-23,269**	**-131,683**

In the parent company, there are no items reported as other comprehensive income, which is why total comprehensive income corresponds to the period's result.

Parent Company Balance Sheet

Assets

Amounts in SEK thousands	June 30 2026	June 30 2025	December 31 2025
ASSETS			
Non-current assets			
Intangible fixed assets	64,050	56,714	60,743
Property plant and equipment	3,664	3,829	3,943
Financial assets	113,303	113,014	108,760
Total non-current assets	**181,017**	**173,557**	**173,446**
Current assets			
Inventories	15,275	24,978	15,781
Trade receivables and other receivables	4,917	6,207	11,613
Receivables from Group companies	4,057	29,798	7,705
Prepaid expenses and accrued income	2,492	2,716	3,826
Cash and bank balances	32,262	129,033	70,070
Total current assets	**59,003**	**192,732**	**108,996**
TOTAL ASSETS	**240,020**	**366,289**	**282,442**

Parent Company Balance Sheet

Equity and Liabilities

Amounts in SEK thousands	June 30 2026	June 30 2025	December 31 2025
EQUITY AND LIABILITIES			
Equity			
Restricted equtiy	87,385	79,768	83,981
Non-restricted equity	97,585	241,641	132,558
Total equity	**184,970**	**321,409**	**216,539**
LIABILITIES			
Interest-bearing liabilities	7,500	-	-
Provisions	4,378	4,547	4,614
Total non-current liabilities	**11,878**	**4,547**	**4,614**
Current liabilities			
Trade payables	3,611	6,183	7,618
Liabilities to Group companies	28,618	21,695	40,269
Other current liabilities	1,136	3,281	1,774
Accrued expenses	9,807	9,174	11,627
Total current liabilities	**43,172**	**40,333**	**61,289**
TOTAL EQUITY AND LIABILITIES	**240,020**	**366,289**	**282,442**

Notes on the consolidated accounts

Note 1. Accounting policies

This interim report and summary for the second quarter ended June 30th, 2026 has been prepared in accordance with the international accounting standard IAS 34 "Interim reporting". The term "IFRS" in this document includes the application of IAS and IFRS, as well as interpretations of these recommendations published by the IASB's Standards Interpretation Committee (SIC) and IFRS Interpretation Committee (IFRIC)

The application of the accounting principles is consistent with those in the Annual Report for the financial year ended 31 December 2025 and should be read in conjunction with this interim report. There are no changes to IFRS in 2026 that are estimated to have a material impact on the results and financial position of the Group. Unless otherwise stated, all amounts are reported in thousands of Swedish kronor (SEK KS). Information in parentheses refers to the comparative year.

Note 2. Division of net Sales

	Q2		Jan-Jun		Full-year
Amounts in SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Devices/Other	4,808	11,896	10,271	21,133	38,194
- there of royalties	*180*	*118*	*231*	*272*	*665*
Disposables	19,863	13,800	37,633	28,062	65,828
Total	**24,671**	**25,695**	**47,904**	**49,195**	**104,022**

Note 3. Costs of goods sold

	Q2		Jan-Jun		Full-year
Amounts in SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Cost of materials	6,526	8,033	13,091	14,876	41,850
Personnel expenses	612	472	1,185	1,155	2,447
External services	1,182	1,210	2,504	1,514	4,145
Depreciation and amortization	5,483	5,063	10,580	10,332	20,888
Total	**13,803**	**14,778**	**27,360**	**27,877**	**69,330**

Note 4. Development, selling and administrative expenses by nature of cost

	Q2		Jan-Jun		Full-year
Amounts in SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Personnel expenses	22,202	27,271	47,205	50,529	100,384
Consulting expenses	5,166	5,754	9,939	12,699	25,252
Depreciation and amortization	714	752	1,423	1,726	3,503
Other expenses	5,999	6,584	11,467	11,836	26,532
Total	**34,081**	**40,361**	**70,034**	**76,790**	**155,671**

Note 5. Transactions with related parties

During the period, one board member has invoiced TSEK 576 (609) on market terms, for performed consulting services linked to the company's operational activities. The services are performed by Sorin Brull.

Note 6. Earnings per share

SEK	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Basic earnings per share	-0.14	-0.24	-0.28	-0.50	-0.93
Diluted earnings per share	-0.14	-0.24	-0.28	-0.50	-0.93
Performance measure used in the calculation of earnings per share					
Results attributable to the parent company's shareholders are used	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period
Result attributable to the parent company's shareholders, SEK thousand	-21,361	-34,349	-43,873	-69,011	-137,419
No.					
Weighted average no. of ordinary shares for calculating basic earnings per share	157,215,046	140,722,824	157,215,046	136,955,877	147,067,962
Stock options					
Weighted average no. of ordinary shares and potential shares used as denominator for calculating diluted earnings per share	157,215,046	140,722,824	157,215,046	136,955,877	147,067,962

Earnings per share after dilution are not reported as it gives better earnings per share because the period's earnings are negative.

Note 7. Share capital development

Date	Event	Number of shares	Share capital (SEK)	Quotient value (SEK)
January 1, 2024	Opening balance	119,705,523	14,963,190	0.125
October 18, 2024	Right share issue part 1	12,769,000	1,596,125	0.125
December 19, 2024	Right share issue part 2	700,000	87,500	0.125
February 24, 2025	Set-off share issue RMI - Final	40,523	5,066	0.125
June 12, 2025	Right share issue part 1	23,300,000	2,912,500	0.125
July 10, 2025	Right share issue part 2	700,000	87,500	0.125
Total June 30, 2026		**157,215,046**	**19,651,881**	**0.125**

Note 8. Alternative performance measures

Senzime has defined alternative key figures as below. Calculations are published on the company's websitewww.senzime.com.

Performance measure	Definition	Motive for use
Gross margin excl. amortization	Gross profit (loss) excl. amortization of intangible assets divided by net sales	The group uses the alternative performance measure gross margin excluding amortization because it illustrates the impact of amortization of capitalized development expenditure on gross margin.
EBITA	Earnings before interest and taxes excluding amortization of intangible assets	The group uses the alternative performance measure EBITA because it illustrates the impact of amortization of capitalized development expenses on operating profit.
Equity/assets ratio	Closing equity in the period divided by closing total assets in the period	The group uses the alternative performance measure equity/assets ratio because it illustrates the portion of the total assets that consist of equity and has been included so investors will be able to assess the group's capital structure.
Items affecting comparability	Items of material value that do not have any clear relationship with ordinary activities and are of such nature that they cannot be expected to occur often. They may, for example, relate to acquisitions, major one-off orders, other unusual non-recurring revenue and expenses, capital gains/losses from divestments, restructuring expenses and impairment losses.	Enables improved understanding of the company's underlying operations.
Currency fluctuations	Adjusted for currency fluctuations on the net sales of operations excludes the effect of exchange rates by restating the net sales of operations for the relevant period by applying the rates of exchange used for the comparative period.	This performance measure is important for understanding the underlying progress of operations, and improves compatibility between periods

Note 9. Alternative performance measures

		Q2		Jan-Jun		Full-year
		2026	2025	2026	2025	2025
A	Net sales, TSEK	24,671	25,695	47,904	49,195	104,022
B	Gross profit excl. amortization, TSEK	16,221	15,881	30,872	31,366	54,712
B/A	**Gross margin excl. amortization (%)**	**65.7%**	**61.8%**	**64.4%**	**63.8%**	**52.6%**

		Q2		Jan-Jun		Full-year
	Amounts in SEK thousands	2026	2025	2026	2025	2025
A	Earnings before interest and taxes	-23,333	-29,291	-49,219	-56,187	-122,575
B	Depreciation and amortization	6,066	5,718	11,750	11,776	23,524
A+B	**EBITDA**	**-17,267**	**-23,573**	**-37,469**	**-44,411**	**-99,051**

		Q2		Jan-Jun		Full-year
	Amounts in SEK thousands	2026	2025	2026	2025	2025
A	Equity	263,840	371,400	263,840	371,400	304,461
B	Total assets	325,401	435,219	325,401	435,219	369,811
A/B	**Equity/assets ratio, (%)**	**81.1%**	**85.3%**	**81.1%**	**85.3%**	**82.3%**

Note 10. Employee stock option programs

Dilution from stock option programs

At the Annual General Meeting in May 2026, it was decided to grant another employee stock option program with a total maximum of 2,400,000 options and during June 2026, 1,545,000 employee stock options and 240,000 hedge options were granted. At the time of publication of this interim report, there are five employee stock option programs with a total of 5,950,000 granted options and 700,000 hedge options. During the period January-June 2026, of the five employee stock option programs, 185,000 employee stock options have expired. A total of 489,000 employee stock options has expired to date and the remaining 5,461,000 employee stock options would, if fully exercised, result in a dilution of 3.92 percent. The corresponding figure excluding hedge options is 3.47 percent

Note 11. Board shareholder program

Annual General Meeting in May 2026 resolved on the implementation of a shareholder program for board members of Senzime ("Board Program 2026"). Adam Dahlberg, connected to the Company's largest shareholder – the Crafoord family and the Crafoord Foundation, and Lars Axelsson, connected to the Company's second-largest owner, the Segulah group, are not included in Board Program 2026. More information including terms for the Board Program 2026 can be find under AGM “Notice” and “Minutes” visiting Shareholder Meetings | Senzime.

Financial calendar

Interim report Q3 2026	29 Oct 2026
Year-End report Q4 2026	18 Feb 2027
Interim report Q1 2027	22 Apr 2027
Annual report 2026	23 Apr 2027

Contact

Philip Siberg, CEO
Tel. +46 (0) 707 90 67 34
e-post: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Tel. +46 (0) 763 06 60 11
e-post: slavoljub.grujicic@senzime.com